AI, robotic experimentation and quantum physics for drug and materials discovery.
Related updates
image credit- shutterstock China's XtalPi Holdings, an AI and robotics-driven drug and materials discovery company, has debuted Kodexia™, the industry's first closed-loop small interfering RNA (siRNA) discovery platform combining generative AI, first-principles-driven biological modeling, and automated experimentation. Validating the rapid execution capabilities of this new infrastructure, the company simultaneously
**media[1229066]**Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities.Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC.MPER vaccine immunogens elicit antibody levels approximately five times those of the study comparator in rhesus mac
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR). The collaboration follows a successful pilot phase, where XtalPi’s integrated quantum physics and AI algorithms achieved improved hit rates, highlighting the platform’s capability to address the complex metabolic